Press release
Masimo SET® Pulse Oximetry: Superior Performance, Worldwide Presence, Immeasurable Impact
Masimo SET® Is the Primary Pulse Oximetry at All 10 Top U.S. Hospitals, Monitors More Than 200 Million Patients a Year, and Has Been Shown to Have Unrivaled
About this update from Masimo Corporation
[{"type":"text","content":"\nMasimo SET® Is the Primary Pulse Oximetry at All 10 Top U.S. Hospitals, Monitors More Than 200 Million Patients a Year, and Has Been Shown to Have Unrivaled Accuracy and Reliability in More Than 100 Clinical Studies\n\n\n IRVINE, Calif.--(BUSINESS WIRE)--\nMasimo (NASDAQ: MASI) Signal Extraction Technology®, or SET®, pulse oximetry – industry-leading, clinically proven, and used by top hospitals everywhere – continues to overcome the limitations of conventional pulse oximetry and offers unrivaled accuracy through ongoing innovation. As of 2024, Masimo’s foundational SET® technology is now the primary pulse oximetry technology at all ten top U.S. hospitals,1 and is used to monitor more than 200 million patients a year around the world.2 With more than 100 studies demonstrating its ability to outperform other pulse oximetry technologies,3 SET® measures with industry-best SpO2 accuracy specifications4 – achieved with Masimo’s flagship RD SET® sensors – through challenging conditions such as patient motion and low perfusion, across all patient populations, and on all skin tones. With decades of expertise, Masimo is now able to make SET® available not only for traditional hospital bedside monitoring, but in tetherless sensors that promote freedom of movement, in wearable devices worn at home, in baby monitors, and in opioid overdose monitoring solutions – among many others.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240825566466/en/Masimo SET® Pulse Oximetry (Graphic: Business Wire)\nSuperior Performance\n\n\nMasimo SET® originated in Founder and CEO Joe Kiani’s desire to find a way to monitor the oxygen saturation of those most precious of patients – neonatal infants – accurately and reliably, even though their frequent movement and poor perfusion stymied traditional pulse oximetry. SET® overcame those seemingly insurmountable obstacles, and Masimo’s continued innovation is driving significant accuracy and reliability milestones even today.\n\n\n\nMasimo SET® is accurate during motion. Before Masimo SET® pulse oximetry, false alarm rates were high,5,6 often due to motion7,8 and low perfusion.7 With Masimo SET®, the rate of false alarms dropped by more than 80% and yet true alarm detection improved significantly.7,8\n\n\n\nMasimo SET® is accurate during low perfus...